Guilford-based AI Therapeutics, a drug company founded by entrepreneur Jonathan Rothberg, has acquired a new cancer drug candidate from Spain’s EntreChem, S.L.
The new candidate, EC-8042 (now AIT-102), is in development as a treatment for rare pediatric and other cancers.